Partly. Novo Nordisk announced on February 24, 2026 that Wegovy’s US list price falls about 50% on January 1, 2027, to $675 a month. But list price is not what most people pay. Novo said the change does not affect its self-pay prices, and a flat copay may not move at all. [1]
This article covers pricing and coverage only. Talk to your prescriber about treatment decisions.
What exactly did Novo Nordisk announce?
One number, one date, three medicines.
Effective January 1, 2027, Novo Nordisk will lower the list price — the wholesale acquisition cost, or WAC — to $675 for: [1]
- Wegovy injection 2.4 mg and tablets 25 mg
- Ozempic injection 0.5 mg, 1 mg, and 2 mg
- Rybelsus tablets 7 mg or 14 mg
Novo describes the reductions as “approximately 50% and 35% for Wegovy and Ozempic, respectively, from the current list price,” and says the decision “applies to all doses of these medicines.” [1]
Two things the announcement also said, in Novo’s own words, matter as much as the headline:
- “These changes in list price do not have an impact on direct-to-patient, self-pay prices.” [1]
- The lower price is aimed at people “whose out-of-pocket costs are linked to list price, such as individuals with high-deductible health plans or co-insurance benefit designs.” [1]
That second sentence is the company telling you who this is for. If your cost is not linked to list price, Novo is not promising you anything.
One more caution: this is an announcement, not a receipt. The date is more than four months out from this writing. Nothing has changed at any pharmacy counter yet.
What is a “list price,” and why isn’t it your price?
Think of three different prices for the same box.
List price is the sticker the manufacturer sets. Novo’s own page puts it plainly: “List price is the original price set for a medication by a manufacturer before any discounts or rebates are applied. However, most people don’t pay list price if they have health insurance.” [2]
Net price is what a health plan actually pays after rebates. Pharmacy benefit managers, or PBMs, negotiate those rebates with manufacturers in exchange for good placement on the plan’s drug list. Those rebate dollars go to the plan and the PBM. KFF notes PBMs “may retain a portion of the drug rebates they negotiate,” and that the rebate system can push PBMs to favor higher-priced drugs because bigger sticker prices support bigger rebates. [7]
Cash or self-pay price is a separate menu entirely — what the manufacturer charges someone paying directly, outside insurance. It is set independently of the list price, which is exactly why Novo could cut one without touching the other.
Here is the part that decides whether the cut reaches you. KFF points out that patient cost sharing “is calculated as a percentage of the drug’s price, which is typical for higher-cost specialty drugs.” [7] A percentage of a smaller number is a smaller number. A flat copay — $30, $50, $75 — is a fixed dollar amount that does not care what the sticker says.
And the sticker cut may not shrink what your employer pays. Mercer, writing two days after the announcement, expects “no meaningful change in net costs after rebates,” because a manufacturer that lowers list price will generally shrink the rebate alongside it. Mercer expects members with coinsurance to see lower out-of-pocket costs, while employers may carry a larger share of the total. [8] That is Mercer’s expectation, not a settled fact.
What will each medicine cost — today’s list price versus January 2027?
Every figure below was read directly off Novo Nordisk’s own pages on August 31, 2026 and re-verified on September 10, 2026.
| Medicine | List price today | Announced list price, Jan 1, 2027 | Self-pay price today at NovoCare | Does the cut change the self-pay price? |
|---|---|---|---|---|
| Wegovy pen (0.25–2.4 mg) | $1,349.02 / package [2] | $675 [1] | $349/mo standard; $199/mo for the first 2 fills for new patients, through Dec 31, 2026 [4] | No — Novo says self-pay is unaffected [1] |
| Wegovy HD pen (7.2 mg) | $1,349.02 / package [2] | $675 [1] | $399/mo [4] | No [1] |
| Wegovy pill | $1,349.02 / package [2] | $675 [1] | $149/mo (1.5 mg), $199/mo (4 mg), $299/mo (9 mg and 25 mg) [4] | No [1] |
| Ozempic pen (0.5, 1, 2 mg) | $1,027.51 / package [3] | $675 [1] | $349/mo for 0.25–1 mg; $499/mo for 2 mg; $199/mo for the first 2 fills for new patients, through Dec 31, 2026 [5] | No [1] |
| Ozempic pill (1.5, 4, 9 mg) | $1,027.51 / package [3] | $675 [1] | $149/mo (1.5 mg), $199/mo (4 mg), $299/mo (9 mg) [5] | No [1] |
| Rybelsus (7 mg, 14 mg) | Not published on Novo’s list-price pages | $675 [1] | Not published | No [1] |
Look at the last two columns together. Every self-pay price Novo publishes today is already below the announced $675 list price. For someone paying cash through NovoCare, January 2027 is not a discount event.
Our own arithmetic on the two verified numbers: $1,349.02 down to $675 is a 49.96% cut, and $1,027.51 down to $675 is a 34.3% cut. Both match what Novo described.
Who is most likely to save in 2027?
Three groups, all for the same reason — their cost is tied to the sticker.
People with coinsurance. If your plan charges you 20% or 30% of the drug’s price instead of a flat dollar copay, a lower price flows straight through to you. This is the group Novo named in its own announcement. [1]
People in a high-deductible plan who have not met the deductible. Before the deductible is met, you generally pay the plan’s negotiated price for the drug. A lower starting point means a smaller bill and a deductible that fills more slowly. Novo named this group too. [1]
Some cash buyers at a regular pharmacy counter. A retail cash price is built off what the pharmacy paid, which tracks list. That is a different lane from Novo’s own self-pay program, which Novo says is unaffected. [1] Whether a given pharmacy passes the lower list price through is a question for that pharmacy.
Who probably won’t see a change?
NovoCare self-pay buyers. Novo said it directly. Your $149, $199, $299, $349, $399, or $499 is set by the self-pay program, not by the list price. [1] [4] [5]
Medicare GLP-1 Bridge enrollees. CMS charges eligible beneficiaries a $50 copay, and the demonstration runs from July 1, 2026 through December 31, 2027. That $50 is a fixed amount. CMS also notes the Part D deductible does not apply and no part of the $50 counts toward your true out-of-pocket costs. [9]
Medicare Part D members generally. Part D already has a separate 2027 number. CMS negotiated a maximum fair price of $274 per 30-day supply for Ozempic, Rybelsus, and Wegovy, effective January 1, 2027, against a 2024 list price of $959 — a 71% discount. That is a different program with a different price, and it is lower than $675. [10]
Medicaid enrollees. Medicaid copayments are already capped at nominal amounts — KFF cites up to $4 for preferred drugs and $8 for non-preferred drugs for people at or below 150% of the federal poverty level, with some groups exempt from cost sharing entirely. There is not much room below that for a list-price cut to help. [11]
Anyone on a flat copay whose plan keeps the same design. If you pay $40 today because your plan says tier 3 costs $40, you will pay whatever your 2027 plan documents say tier 3 costs.
And a coverage caveat. A lower list price does not obligate any plan to start covering a drug it excludes today. Mercer’s read is that lower list prices give employers more room to tighten rules — BMI criteria, lifestyle-program requirements, narrowing to higher-risk groups — because the rebate tradeoff changes. [8]
What should I do between now and January?
Cost-side steps only. Nothing here is a treatment recommendation.
- Do not wait for January on the assumption it will be cheaper. For self-pay buyers, the published prices today are already below $675. Compare what you can actually get now against what is announced.
- Find out how your plan charges you. Look for the word coinsurance or a percentage in your Summary of Benefits and Coverage. A percentage means the cut can reach you. A flat dollar amount means it probably will not. Our insurance coverage guide walks through where to look.
- Read your 2027 plan documents during open enrollment. Your 2027 tier, deductible, and prior-authorization rules will do more to your bill than any manufacturer headline.
- Note the dates on current offers. Novo lists the $199 new-patient pen pricing for Wegovy and Ozempic as 2 monthly fills running through December 31, 2026, after which it steps up to the standard $349–$499 a month. [4] [5] Offer end dates are not the same thing as the January 1 list-price change, and an offer that expires in December can raise your cost in the same month the list price falls.
- Check whether your situation qualifies for something better than $675. The Medicare GLP-1 Bridge at $50, a commercial savings card at as little as $25 a month with a $100 monthly savings maximum, and NovoCare self-pay are all separate lanes. [6] [9] Our cheapest GLP-1 options guide and the Price Check tool compare them side by side.
- Expect some noise at the pharmacy in late December. Mercer told employers to anticipate temporary pharmacy inventory delays ahead of January 2027 as the channel adjusts. [8] Refilling with a little margin is a reasonable planning step.
What about Zepbound and other competitors?
As of August 31, 2026, we found no Eli Lilly announcement of a matching US list-price cut for Zepbound or Foundayo. Lilly’s published price changes have been to its self-pay channels — for example, Zepbound KwikPen self-pay pricing starting at $299 a month at LillyDirect and at major pharmacies, announced March 16, 2026. [12]
We are not going to guess at what Lilly does next. If a verified announcement lands, it will show up in the GLP-1 Price Index and this page will be updated.
How will we know what the real prices are?
By checking in January and telling you what we find.
The honest state of things on September 10, 2026 is that one company has announced one number for one date, and the two sources that would tell you what it means for your wallet — your 2027 plan documents and the actual January pharmacy prices — do not exist yet. We will re-verify Novo’s list-price pages, the NovoCare self-pay pages, and every channel in the GLP-1 Price Index the week the change takes effect, and update this page with what actually happened rather than what was announced.
The short version
Wegovy’s list price is scheduled to fall about 50%, to $675, on January 1, 2027. Whether your price falls depends on one question: is your share a percentage of the drug’s price, or a fixed dollar amount? Percentage, and the cut likely reaches you. Fixed, and it likely does not. Novo has said its self-pay prices are not affected, and those prices are already below $675.
Check your 2027 plan documents, not the headline. And talk to your prescriber about any decision that involves your treatment rather than your bill.
